º£½ÇÉçÇø

  • Adolescent receiving the HPV vaccine

The high disease burden of cervical cancer in the Americas represents a major public health problem that must be addressed through a comprehensive and interprogrammatic strategy (sexual and reproductive health, adolescent health, immunization and cervical cancer control). Cervical cancer is a disease with a long natural history and therefore offers multiple opportunities for intervention throughout a woman's life through effective primary and secondary prevention strategies together with adequate diagnostic and therapeutic management of cases, including access to palliative care.

Key facts
  • In 2022, more than 78,000 women were diagnosed with cervical cancer, and more than 40,000 died from the disease in the Region of the Americas. 
  • Mortality rates are 3 times higher in Latin America and the Caribbean than in North America, highlighting huge health inequalities.

  • Vaccination against the human papillomavirus (HPV) in adolescent women can prevent about 70% of cases of cervical cancer.

  • Screening, followed by treatment of identified precancerous lesions, is a cost-effective prevention strategy. 

Fact sheet

New Tools for Cervical Cancer Prevention and Control

Cervical cytology (Pap test) has historically been used for the early detection of cervical cancer. In many developing countries, including countries in Latin America and the Caribbean (LAC), the use of cytology has not been accompanied by a reduction in mortality comparable to that recorded in developed countries. The failure of screening programs in LAC is not only due to the limitations of cytology as a screening test but also to the organization of health services and different access and cultural barriers. In this context, the development and availability of new screening technologies, as well as HPV vaccines, offer unprecedented opportunities to achieve cervical cancer prevention and control.

  • Safe and effective prophylactic vaccines against oncogenic HPV types are available, allowing for the primary prevention of approximately 70% of cervical cancer cases caused by these HPV types.

  • Cervical cancer screening with high-throughput tests, such as the HPV DNA test, is recommended.

  • Screening using the HPV test is effective and feasible, especially when accompanied by treatment of precancerous lesions with thermal ablation or cryotherapy ("see and treat" Strategy).

  • A comprehensive public health strategy is needed to address cervical cancer control, which involves vaccination of adolescents (where affordable and sustainable), screening of women at risk for cervical cancer (women aged 35 years or older), and treatment of all women with precancerous lesions and invasive cancer.

The scientific evidence in favor of new technologies for the prevention of cervical cancer is clear and well-established. In addition, sufficient quality research studies carried out in Latin American countries support these results with data from the region. Furthermore, the implementation of these new technologies is feasible, as shown by the successful experiences of some countries. All of this indicates that the region is at a turning point where the right conditions are in place for the incorporation of changes in cervical cancer prevention and control programs that will allow for a positive impact on the burden of disease. 

º£½ÇÉçÇø Response

In 2018, the 56th Directing Council of the º£½ÇÉçÇø (º£½ÇÉçÇø) approved the Action Plan for the Prevention and Control of Cervical Cancer 2018-2030 to prevent and control this disease. The main objective of this Plan is to help Member States develop comprehensive cervical cancer control programs. In 2020, the World Health Organization (WHO) launched a strategy to accelerate the elimination of cervical cancer as a public health problem, with specific targets for vaccination, screening, and treatment. To achieve this goal, the Strategy proposes three objectives for countries by 2030:

• 90% HPV vaccination coverage in girls (at 15 years of age);

• 70% screening coverage (70% of women undergo high-performance testing at ages 35 and 45 years);

• 90% treatment of precancerous lesions and management of 90% of invasive cancer cases. 

The º£½ÇÉçÇø is actively helping countries in the region improve the effectiveness of their cervical cancer prevention and control programs. This is done by creating national plans to eliminate cervical cancer based on the need to increase HPV vaccination coverage, support the implementation of HPV testing, and improve the availability of treatments for premalignant lesions and cancer. Likewise, º£½ÇÉçÇø is providing technical support to improve information systems in order to monitor and evaluate actions and progress toward eliminating cervical cancer as a public health problem. 

 

{"preview_thumbnail":"/sites/default/files/styles/video_embed_wysiwyg_preview/public/video_thumbnails/pkUmJlvHwQA.jpg?itok=4sp6tcYr","video_url":"","settings":{"responsive":true,"width":"854","height":"480","autoplay":false},"settings_summary":["Embedded Video (Responsive)."]}


Useful Links:

 

Resources for health professionals

ECHO Latin America ELA Project

Sessions

The inaugural meeting of the ECHO Latin America ELA Project: Monthly Teleconferences on Cervical Cancer Prevention Programs was held on Friday, May 29, 2020.

During the inaugural meeting, the collaborators of the ECHO ELA Project: Silvana Luciani, º£½ÇÉçÇø (º£½ÇÉçÇø), Melissa Lopez Varon, University of Texas MD Anderson Cancer Center, and Sandra L. San Miguel, National Cancer Institute of the States Unidos (NCI) welcomed 140 participants, including those in charge of the national cervical cancer and immunization programs of the Latin American Ministries of Health; representatives of NGOs and professional associations working on the issue; º£½ÇÉçÇø Focal Points from each country, º£½ÇÉçÇø representatives from Washington, D.C., WHO Geneva, the University of Texas MD Anderson Cancer Center, the United States National Cancer Institute, and collaborators related to the subject.

Read More...

The second monthly meeting of the ECHO Latin America ELA Project: Monthly Teleconferences on Cervical Cancer Prevention Programs was held on Friday, June 26, 2020.

During the meeting, the collaborators of the ECHO ELA Project: Silvana Luciani, º£½ÇÉçÇø (º£½ÇÉçÇø), Melissa López Varon, University of Texas MD Anderson Cancer Center (MDACC) and Sandra San Miguel, of the National Cancer Institute of the States Unidos (NCI), and the members of the Faculty, Drs. Silvina Arrossi (Argentina), Maria Tereza da Costa (OPS / WDC / Brazil), Mauricio Maza (El Salvador) and Mila Salcedo (MDACC / Brazil) gave them the welcomed 119 participants, including those in charge of the national cervical cancer and immunization programs of the Latin American Ministries of Health; representatives of NGOs and professional associations working on the issue; º£½ÇÉçÇø Focal Points from each country, º£½ÇÉçÇø representatives from Washington, D.C., WHO Geneva, the University of Texas MD Anderson Cancer Center, the United States National Cancer Institute, and collaborators related to the subject.

MORE INFORMATION

The third monthly meeting of the ECHO Latin America ELA Project: Monthly Teleconferences on Cervical Cancer Prevention Programs was held on Friday, July 31, 2020.

During the meeting, ECHO ELA Project collaborators: Melissa Lopez Varon, University of Texas MD Anderson Cancer Center (MDACC) and Sandra L. San Miguel, United States National Cancer Institute (NCI), and members of the Faculty , Drs. Silvina Arrossi (Argentina), Maria Tereza da Costa (º£½ÇÉçÇø / WDC / Brazil), Mauricio Maza (El Salvador) Jane Montealegre (BCM) and Mila Salcedo (MDACC / Brazil) welcomed 108 participants, including those in charge of the national programs of cervical cancer and immunizations of the Ministries of Health of Latin America; representatives of NGOs and professional associations working on the issue; º£½ÇÉçÇø Focal Points from each country, º£½ÇÉçÇø representatives from Washington, D.C., WHO Geneva, the University of Texas MD Anderson Cancer Center, the United States National Cancer Institute, and collaborators related to the subject.

MORE INFORMATION

Virtual courses on cervical cancer
Video

It´s time to end cervical cancer

Las niñas en Tarija reciben la vacuna de VPH

Prevención de cáncer cervicouterino mediante la prueba de VPH en México

Latest news

Stories

Documents

Communication Materials

Mandates and Strategies

Events

More information